arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Tenaya Therapeutics, Inc.

TNYA

$0.73 0.00 (+0.03%) at close

7 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Tenaya Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $111.7M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -75.7% ↗

FCF / Share $-0.45 ↗

Trailing P/E —

Price / Book 1.3x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-90.60M

↑ +18.5% —

FCF / Share Free cash flow per share

$-0.45

↑ +58.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	55.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	22.0% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	39.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	32.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	18.5% Good ↑ Good Improving Year-over-year change in net income	10.4% Fair ↑ Fair Improving Year-over-year change in net income	-0.3% Weak ↑ Weak Improving Year-over-year change in net income	-70.1% Weak Weak Year-over-year change in net income	-89.4% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	58.3% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	22.9% Good ↓ Good Declining Year-over-year change in free cash flow	49.8% Excellent Excellent Year-over-year change in free cash flow	42.4% Excellent Excellent Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	0.76x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.01x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	1.18x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	1.18x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-75.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-124.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-94.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-51.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-26.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	47.9% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-63.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-96.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-76.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-45.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-23.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-26.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-73.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-590%)	-119.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-898%)	-89.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-693%)	-50.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-439%)	-26.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-274%)	47.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+215%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Net Debt (USD)	$-100.55M	$-4.32M	$-45.68M	$-95.27M	$-38.13M	$-128.53M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-0.59	$-1.31	$-1.68	$-2.76	$-4.10	—	—
Free Cash Flow per Share (USD)	$-0.45	$-1.08	$-1.40	$-2.79	$-4.85	—	—
Book Value per Share (USD)	$0.57	$1.07	$2.04	$3.64	$6.75	$-67.19	—
Tangible Book Value per Share (USD)	$0.57	$1.07	$2.04	$3.64	$6.75	$-67.19	—
Basic Weighted Avg Shares (shares)	152.97M	84.82M	73.79M	44.82M	17.73M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$90.15M	$51.40M	$88.85M	$169.51M	$233.58M	$124.92M	—
Total Equity (USD)	$123.27M	$92.85M	$139.42M	$243.38M	$278.53M	$-81.31M	$-43.74M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	$8.44M	$8.47M	$8.69M	$6.47M	$2.96M	$2.48M	—
Net Income, GAAP (USD)	$-90.60M	$-111.13M	$-124.08M	$-123.67M	$-72.72M	$-38.40M	—
Operating Cash Flow (USD)	$-68.26M	$-90.50M	$-102.07M	$-104.42M	$-60.81M	$-35.45M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Tenaya Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare TNYA with peers